Download PDF
Notfall & Hausarztmedizin 2009; 35(6): 304-308
DOI: 10.1055/s-0029-1233547
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Basalzellkarzinom – ein Tumor mit guter Prognose – Epidemiologie, Klinik und Therapie

Basal cell carcinoma: a tumour with good prognosis – Epidemiology, clinic and therapyDimitrios Georgas1 , Falk G. Bechara1
  • 1Abt. Operative Dermatologie, Klinik für Dermatologie und Allergologie, Ruhr-Universität Bochum (Direktor: Prof. Dr. med. Peter Altmeyer)
Further Information

Publication History

Publication Date:
30 June 2009 (online)

    Permissions and Reprints

Das Basalzellkarzinom ist die häufigste Krebsform des Menschen. Es tritt vor allem in sonnenexponierten Arealen der Haut auf. Meist wächst der Tumor langsam, und er metastasiert in der Regel nicht. Ein infiltratives und destruierendes Wachstum unter Einbeziehung tiefer Gewebestrukturen ist jedoch möglich. Bei frühzeitiger adäquater Behandlung ist die Prognose sehr gut. Therapie der Wahl ist die operative Sanierung.

Basal cell carcinoma is the most common malignancy in humans. It typically occurs in areas of chronic sun exposure. Basal cell carcinoma is usually slow growing and rarely metastasizes, but it can cause clinically significant local destruction and disfigurement if neglected or inadequately treated. Prognosis is excellent with proper therapy, with surgery being the method of choice.

Key words

basal cell carcinoma - chronic sun exposure - clinics - therapy - prognosis

Literatur

  • 1 Breuninger H, Garbe K.. Basalzellkarzinom.  Hautarzt. 1998;  10
    PubMedGoogle Scholar
  • 2 Dissemond J, Garbe S.. Basalzellkarzinom – Ein Überblick.  Dtsch Med Wochenschr. 2004;  129 2255-2260
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Drake LA, Ceilley RI, Cornelison RL. et al. . Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care.  J Am Acad Dermatol. 1992;  26 117-120
    CrossrefPubMedGoogle Scholar
  • 4 Geisse J, Caro I, Lindholm J. et al. . Imiquimod 5  % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.  J Am Acad Dermatol. 2004;  50 722-733
    CrossrefPubMedGoogle Scholar
  • 5 Heenan PJ, Elder DJ, Sobin LH.. Histological typing of skin tumours. 26. WHO International Histological Classification of Tumours. Berlin, Heidelberg, New York, Tokyo: Springer 1996
    Google Scholar
  • 6 Breuninger H, Sebastian G, Kortmann RD. et al. .Deutsche Leitlinie: Basalzellkarzinom. In: Garbe C (Hrsg.) Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Stuttgart, New York: Georg Thieme Verlag 2005: 1-11
    Google Scholar
  • 7 Garbe C.. Epidemiologie des Hautkrebses. In: Garbe C, Dummer R, Kaufmann R, Tilgen W (eds). Dermatologische Onkologie. Berlin, Heidelberg, New York, Tokio: Springer 1997: 40-56
    Google Scholar
  • 8 Thomas DJ, King AR, Peat BG.. Excision margins for nonmelanotic skin cancer.  Plast Reconstr Surg. 2003;  2 57-63
    PubMedGoogle Scholar
  • 9 Euvrad S, Kanitakis J, Claudy A.. Skin cancers after organ transplantation.  N Engl J Med. 2003;  348 1681-1691
    CrossrefPubMedGoogle Scholar
  • 10 Nickoloff BJ, Qin JZ, Chaturvedi V. et al. . Life and death signalling pathways contributing to skin cancer.  J Invest Dermatol Symp Proc. 2002;  7 27-35
    PubMedGoogle Scholar
  • 11 Tran H, Chen K, Shumack S.. Epidemiology and aetiology of basal cell carcinoma.  Br J Dermatol. 2003;  149 50-52
    CrossrefPubMedGoogle Scholar
  • 12 Woolgar JA, Rippin JW, Taylor M, Browne RM.. The basal cell naevus syndrome.  Br J Hosp Med. 1987;  38 350
    PubMedGoogle Scholar
  • 13 Kopf A.. Computer analysis of 3531 basal cell carcinomas of the skin.  J Derm. 1979;  6 267-281
    PubMedGoogle Scholar
  • 14 Kreusch J, Rassner G.. Auflichtmikroskopie pigmentierter Hauttumoren. Stuttgart, New York: Thieme Verlag 1991
    Google Scholar
  • 15 Bath-Hextall F, Bong J, Perkins W, Williams H.. Interventions for basal cell carcinoma of the skin: systematic review.  BMJ. 2004;  329 705
    CrossrefPubMedGoogle Scholar
  • 16 Rowe DE, Carroll RJ, Day Jr. CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up.  J Dermatol Surg Oncol. 1989;  15
    PubMedGoogle Scholar
  • 17 Kumar P, Watson S, Brain AN. et al. . Incomplete excision of basal cell carcinoma: a prospective multicentre audit.  Br J Plast Surg. 2002;  55 616-622
    CrossrefPubMedGoogle Scholar
  • 18 Szeimies RM, Landthaler M.. Photodynamic therapy and fluorescence diagnosis of skin cancers.  Recent Results Cancer Res. 2002;  160 240-245
    PubMedGoogle Scholar
  • 19 Rhodes LE, de M Rie, Enstrom Y. et al. . Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.  Arch Dermatol. 2004;  140 17-23
    CrossrefPubMedGoogle Scholar
  • 20 Giuffrida TJ, Jimenez G, Nouri K.. Histologic cure of basal cell carcinoma treated with cryosurgery.  J Am Acad Dermatol. 2003;  49 483-486
    PubMedGoogle Scholar
  • 21 Marmur ES, Schmults CD, Goldberg DJ.. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer.  Dermatol Surg. 2004;  30 264-271
    PubMedGoogle Scholar
  • 22 Kagy MK, Amonette R.. The use of imiquimod 5  % cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.  Dermatol Surg. 2000;  26 577-578
    PubMedGoogle Scholar
  • 23 Nijsen TE, Stern RS.. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study.  J Invest Dermatol. 2003;  121 252-258
    CrossrefPubMedGoogle Scholar
  • 24 Pfeiffer P, Hansen O, Rose C.. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature.  Eur J Cancer. 1990;  26 73-77
    PubMedGoogle Scholar
  • 25 Spates Jr ST, Mellete JR, Fitzpatrick J.. Metastatic basal cell carcinoma.  Dermatol Surg. 2003;  29 650-652
    PubMedGoogle Scholar
  • 26 Rowe DE, Carroll RJ, Day Jr. CL. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg.  Oncol. 1989;  15
    PubMedGoogle Scholar
  • 27 Greinert R, Volkmer B, Wende A. et al. . Prävention von Hautkrebs. Notwendigkeit, Durchführung und Erfolg.  Hautarzt. 2003;  54 1152-1163
    CrossrefPubMedGoogle Scholar

1 Tumor, Nodi, Metastasen

Korrespondenz

PD Dr. med. Falk G. Bechara

Klinik für Dermatologie und Allergologie Ruhr-Universität Bochum

Gudrunstraße 56

44791 Bochum

Email: f.bechara@derma.de

      >